MTEM Molecular Templates

Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences

Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences

AUSTIN, Texas, March 05, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that management will provide a corporate overview at the Cowen & Company 39th Annual Health Care Conference, and the Oppenheimer & Co., 29th Annual Health Care Conference.

Cowen & Company 39th Annual Health Care Conference
Date: Monday, March 11
Time:3:30pm Eastern Time
Webcast:/



Oppenheimer & Co 29th Annual Health Care Conference
Date:Tuesday, March 19
Time:8:00am Eastern Time

Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.  For additional information, please visit Molecular Templates’ website at .

Investor Contact:

Adam Cutler

Chief Financial Officer



862-204-4006

Source: Molecular Templates, Inc.

EN
05/03/2019

Underlying

MTEMMolecular Templates

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Templates

 PRESS RELEASE
Free
MTEM Molecular Templ...

Molecular Templates Announces Notice of Delisting and Failure to Satis...

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasda...

December 19, 2024 1 EN
 PRESS RELEASE
Free
MTEM Molecular Templ...

Molecular Templates Announces Receipt of Expected Notification of Defi...

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announc...

December 2, 2024 1 EN
 PRESS RELEASE
Free
MTEM Molecular Templ...

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Result...

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas, Aug...

August 14, 2024 1 EN
 PRESS RELEASE
Free
MTEM Molecular Templ...

Molecular Templates, Inc. Provides Interim Update

Molecular Templates, Inc. Provides Interim Update Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) fo...

June 3, 2024 1 EN
 PRESS RELEASE
Free
MTEM Molecular Templ...

Molecular Templates, Inc. Reports First Quarter 2024 Financial Result...

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company Highlights MTEM presented clinical d...

May 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch